SEC Form S-3MEF filed by Enliven Therapeutics Inc.
As filed with the Securities and Exchange Commission on June 13, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
Under
The Securities Act of 1933
Enliven Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
| Delaware | 81-1523849 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
6200 Lookout Road
Boulder, CO 80301
(720) 647-8519
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Samuel Kintz
President and Chief Executive Officer
Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301
(720) 647-8519
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Tony Jeffries, Esq.
Jennifer Knapp, Esq.
Wilson Sonsini Goodrich & Rosati
Professional Corporation
1881 9th Street, Suite 110
Boulder, CO 80302
(303) 256-5900
Approximate date of commencement of proposed sale to the public: From time to time after the effective date of the registration statement.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File no. 333-272909)
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the registrant is filing this Registration Statement on Form S-3 to register the offer and sale of an additional $40,000,000, or the equivalent thereof, of its (a) shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”); (b) shares of the Company’s preferred stock, $0.001 par value per share (the “Preferred Stock”); (c) the Company’s debt securities (the “Debt Securities”); (d) depositary shares of the Company representing a fractional interest in a share of Preferred Stock (the “Depositary Shares”); (e) warrants to purchase Common Stock, Preferred Stock, Debt Securities or Depositary Shares (the “Warrants”); (f) subscription rights to purchase Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants or units consisting of some or all of these securities (the “Subscription Rights”); (g) purchase contracts of the Company with respect to the securities of the Company (the “Purchase Contracts”); and (h) units consisting of two or more securities described above in any combination (the “Units”) (the Common Stock, the Preferred Stock, the Debt Securities, the Depositary Shares, the Warrants, the Subscription Rights, the Purchase Contracts and the Units are collectively referred to herein as the “Securities”). This Registration Statement relates to the registrant’s Registration Statement on Form S-3 (File No. 333-272909) (the “Prior Registration Statement”), initially filed on June 23, 2023 and declared effective by the Securities and Exchange Commission on July 3, 2023. The required opinion and consents are filed herewith. The additional amount of Securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.
ii
EXHIBIT INDEX
II-1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on June 13, 2025.
| ENLIVEN THERAPEUTICS, INC. | ||
| By: | /s/ Samuel Kintz | |
| Samuel Kintz | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:
II-2
| Signature |
Title |
Date | ||
| /s/ Samuel Kintz Samuel Kintz |
President, Chief Executive Officer and Director (Principal Executive Officer) | June 13, 2025 | ||
| /s/ Benjamin Hohl Benjamin Hohl |
Chief Financial Officer (Principal Financial and Accounting Officer) |
June 13, 2025 | ||
| * Richard Heyman, Ph.D. |
Chairman of the Board of Directors and Director | June 13, 2025 | ||
| * Rahul Ballal, Ph.D. |
Director | June 13, 2025 | ||
| * Jacob Bauer |
Director | June 13, 2025 | ||
| * Mika Derynck, M.D. |
Director | June 13, 2025 | ||
| * Rishi Gupta, J.D. |
Director | June 13, 2025 | ||
| * Lori Kunkel, M.D. |
Director | June 13, 2025 | ||
| * Andrew Phillips, Ph.D. |
Director | June 13, 2025 |
| *By: | /s/ Samuel Kintz | |
| Samuel Kintz | ||
| President and Chief Executive Officer Attorney-in-Fact |